四硫代鉬酸膽鹼

四硫代鉬酸膽鹼
臨床資料
商品名（英語：Drug nomenclature）	Decuprate
其他名稱	四硫代鉬酸雙膽鹼; 雙膽鹼四硫代鉬酸鹽; ATN-224、WTX101
ATC碼	未分配;
法律規範狀態
法律規範	Investigational;
識別資訊
CAS號	649749-10-0
PubChem CID	18442052;
DrugBank	DB05088;
ChemSpider	19906891;
UNII	91U3TGV99T;
化學資訊
化學式	C10H28MoN2O2S4
摩爾質量	432.542 g/mol
3D模型（JSmol（英語：JSmol））	交互式圖像;
	SMILES OCC[N+](C)(C)C.[S-][Mo]([S-])(=S)=S.C[N+](C)(C)CCO;
	InChI InChI=1S/2C5H14NO.Mo.4S/c21-6(2,3)4-5-7;;;;;/h27H,4-5H2,1-3H3;;;;;/q2+1;;;;2-1; Key:NEYVHGQOGHJAAD-UHFFFAOYSA-N;

四硫代鉬酸膽鹼（又稱膽鹼四硫代鉬酸鹽，商品名為Decuprate），是膽鹼所形成的硫代鉬酸鹽（TTM, MoS₄²⁻）。作為威爾遜氏病的治療方法，這是一種身體不能調節銅的罕見且潛在的致命疾病。威爾遜病是一種常染色體隱性遺傳性疾病，有嚴重的肝、神經或精神症狀的表現。若未經診斷和未經治療，該疾病可能致命。據估計，全世界每3萬人中約有1人患有威爾遜氏病，相當於歐盟約有1萬5千人而美國約有1萬1千人。^[1]

已經在患有各種癌症的患者的臨床試驗中評估了四硫代鉬酸膽鹼，^[2]^[3]^[4]並在美國和歐盟成為了孤兒藥（即罕見藥），作為威爾遜氏病的潛在治療方法。^[5]^[6]

四硫代鉬酸膽鹼是威爾遜治療學公司的代號為WTX101的威爾遜氏病臨床開發中的去銅療法用藥，該公司由HealthCap於2012年成立。

參考文獻

^ Ala, A; Walker, A. P.; Ashkan, K; Dooley, J. S.; Schilsky, M. L. Wilson's disease. The Lancet. 2007, 369 (9559): 397–408. PMID 17276780. doi:10.1016/S0140-6736(07)60196-2.
^ Berenson JR, Boccia RV, Bashey A, Levine AM, Koc ON, Callahan JA, Mazar AP, Reich SD. Phase I Study of the [Cu, Zn] Superoxide Dismutase (SOD1) Inhibitor ATN-224 (Bis-Choline Tetrathiomolybdate) in Patients with Advanced Hematologic Malignancies Presentation at the Amer Soc Hematol 2006 Annual Meeting. Blood. 2006, 108. Abstract 2593.
^ Lin, J; Zahurak, M; Beer, T. M.; Ryan, C. J.; Wilding, G; Mathew, P; Morris, M; Callahan, J. A.; Gordon, G; Reich, S. D.; Carducci, M. A.; Antonarakis, E. S. A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer. Urologic Oncology: Seminars and Original Investigations. 2013, 31 (5): 581–8. PMC 3227793  . PMID 21816640. doi:10.1016/j.urolonc.2011.04.009.
^ Lowndes, S. A.; Adams, A; Timms, A; Fisher, N; Smythe, J; Watt, S. M.; Joel, S; Donate, F; Hayward, C; Reich, S; Middleton, M; Mazar, A; Harris, A. L. Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors. Clinical Cancer Research. 2008, 14 (22): 7526–34. PMID 19010871. doi:10.1158/1078-0432.CCR-08-0315.
^ Public summary of opinion on orphan designation: Choline tetrathiomolybdate for the treatment of Wilson's disease （頁面存檔備份，存於互聯網檔案館）, EMA/COMP/795268/2012, ATN-224, 18 February 2013.
^ Orphan Drug Designations and Approvals: choline tetrathiomolybdate （頁面存檔備份，存於互聯網檔案館）, U.S. Food and Drug Administration, 25 August 2011

[1] Ala, A; Walker, A. P.; Ashkan, K; Dooley, J. S.; Schilsky, M. L. Wilson's disease. The Lancet. 2007, 369 (9559): 397–408. PMID 17276780. doi:10.1016/S0140-6736(07)60196-2.

[Berenson-2] Berenson JR, Boccia RV, Bashey A, Levine AM, Koc ON, Callahan JA, Mazar AP, Reich SD. Phase I Study of the [Cu, Zn] Superoxide Dismutase (SOD1) Inhibitor ATN-224 (Bis-Choline Tetrathiomolybdate) in Patients with Advanced Hematologic Malignancies Presentation at the Amer Soc Hematol 2006 Annual Meeting. Blood. 2006, 108. Abstract 2593.

[Lin-3] Lin, J; Zahurak, M; Beer, T. M.; Ryan, C. J.; Wilding, G; Mathew, P; Morris, M; Callahan, J. A.; Gordon, G; Reich, S. D.; Carducci, M. A.; Antonarakis, E. S. A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer. Urologic Oncology: Seminars and Original Investigations. 2013, 31 (5): 581–8. PMC 3227793  . PMID 21816640. doi:10.1016/j.urolonc.2011.04.009.

[Lowndes-4] Lowndes, S. A.; Adams, A; Timms, A; Fisher, N; Smythe, J; Watt, S. M.; Joel, S; Donate, F; Hayward, C; Reich, S; Middleton, M; Mazar, A; Harris, A. L. Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors. Clinical Cancer Research. 2008, 14 (22): 7526–34. PMID 19010871. doi:10.1158/1078-0432.CCR-08-0315.

[5] Public summary of opinion on orphan designation: Choline tetrathiomolybdate for the treatment of Wilson's disease （頁面存檔備份，存於互聯網檔案館）, EMA/COMP/795268/2012, ATN-224, 18 February 2013.

[6] Orphan Drug Designations and Approvals: choline tetrathiomolybdate （頁面存檔備份，存於互聯網檔案館）, U.S. Food and Drug Administration, 25 August 2011

[1]

[2]

[3]

[4]

[5]

[6]